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The risk of venous thromboembolism (VTE) increases 5 - 10-fold 
during pregnancy, and 15 - 35-fold postpartum compared with 
that in non-pregnant women of the same age.[1] High-quality data 
specific to the pregnant patient are lacking, as pregnancy is an 
exclusion criterion in most randomised clinical VTE trials. Most 
guidelines are therefore based on expert opinion and observational 
studies. Pregnancy also deals with maternal and fetal wellbeing. 
Despite these issues, several excellent publications have appeared 
in the past year. The aim of this review is not to replace any of 
these papers, but rather summarise some of the points made. 
The interested reader is advised to read some (if not all) of these 
recommendations, which include those on thromboprophylaxis in 
obstetrics and gynaecology; management of thromboembolism in 
pregnancy; and evidence-based anticoagulation in pregnancy (see 
references 12, 13 and 14).
Why are patients prone to VTE during 
pregnancy?
Various physiological changes[2] that prevent haemorrhage during 
birth and in the weeks after pregnancy lead to a natural hyper-
coagulable state in the pregnant patient (Table 1). Pregnant women 
also experience venous stasis (the enlarging uterus compresses the 
inferior vena cava and pelvic veins). Another VTE risk factor (in the 
well-known Virchow’s triad) is also present, with endothelial changes 
described in pregnancy[4] (including endothelial trauma during 
delivery). 
How many patients develop VTE in 
pregnancy?
Depending on the population studied, VTE complicates 0.5 - 2.2 per 
1 000 deliveries.[1] Pregnancy-related VTE is one of the 10 most important 
potentially preventable causes of maternal death in South Africa (SA).[5] 
In the UK, VTE is the leading direct cause of maternal death (12.9% of 
patients between 2013 and 2015) and the fifth most common cause of 
death overall in pregnancy.[6] Approximately 80% of venous thrombotic 
events are deep-vein thrombosis (DVT) and 20% pulmonary embolism.[7] 
The risk of VTE increases from the time of conception, with the highest 
risk at the time of delivery and immediately thereafter, especially in the 
first 3 - 6 postpartum weeks, with approximately half of VTE events 
occurring during that period. Arterial thrombotic events also increase 
during pregnancy, but are 4 times less common than VTE.[8] 
How do we identify pregnant patients 
at risk of VTE?
All patients should be risk stratified for VTE early in pregnancy if 
admitted to hospital or confined to bedrest during pregnancy, as 
well as in the postpartum period. Various risk factors have been 
classified as high, intermediate or low.[9] Complex scoring systems[9,10] 
have been developed, but no randomised clinical trials have been 
performed to validate these. Patients at high risk of VTE in pregnancy 
should be managed by a team, including a clinical haematologist. 
The risk of bleeding should always be evaluated prior to prescribing 
thromboprophylaxis.
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Table 1. Physiological changes involving coagulation during pregnancy
Increased clotting factors Decreased circulating anticoagulants Reduced fibrinolysis
↑ Factor VIII ↓ Protein S (40 - 60% decrease)[3] ↑ Activity of PAI-1 and PAI-2
↑ Factor X Acquired protein C resistance ↓ Activity of t-PA
↑ Von Willebrand factor - ↑ TAFI levels in third trimester
↑ Factor I (fibrinogen) - -
↑ Factor II - -
↑ Factor VII - -
PAI-1 = plasminogen activator inhibitor-1; PAI-2 = plasminogen activator inhibitor-2; t-PA = tissue plasminogen activator; TAFI = thrombin activatable fibrinolysis inhibitor.
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VTE events are classified as unprovoked events (~50%), indicating 
that there is no known clinical risk factor (e.g. trauma, surgery, active 
cancer, immobility, pregnancy or hormonal usage). Provoked events, 
however, may be due to a transient factor or persistent risk factor. 
Risk of recurrence is highest with provoked persistent risk factors, 
very high with unprovoked risk factors, and lower with transient risk 
factors.[11] In pregnancy, this means that a previous oestrogen-related 
VTE event (persistent provoked risk) and previous unprovoked VTE 
event have a very high risk of recurrence during pregnancy. 
Evaluation of risk factors at time of first consultation or 
antepartum
The patient can be assessed according to risk factors mentioned in 
Royal College of Obstetricians and Gynaecologists (RCOG)[9] and/
or South African Society of Thrombosis and Haemostasis (SASTH)[12] 
articles (Table 2). 
Three important questions must be answered (Fig. 1):
Has the patient previously experienced VTE? 
If confirmative, at least 6 weeks’ postpartum VTE prophylaxis should 
be given. If the event was oestrogen related, unprovoked or more 
than one event occurred, antepartum and postpartum prophylaxis 
are required.[9] Another approach to the recurrent risk in cases of a 
previous VTE, is that all pregnant patients with a previous VTE event 
should receive antepartum and postpartum prophylaxis, unless the 
single previous VTE event was due to a major risk factor.
A familial or acquired clotting tendency (thrombophilia) represents a 
consistent relative increased risk for a first VTE. There is much controversy 
regarding managing patients with known thrombophilia and whether they 
should undergo thrombophilia testing. The second question is therefore:
Does the patient have a family history (first degree) of thrombosis 
or known thrombophilia? Which specific thrombophilia is 
present (including acquired antiphospholipid syndrome)?
One approach has been to grade the different types of thrombo-
philia as severe, intermediate or minor types, and to look at 
events in other family members with the same thrombophilic 
abnormality. Table 3[13,14] summarises the recommendations by 
various authors. It is imperative that the total patient ‘package’ 
must be evaluated, e.g. even though carriers of the factor V Leiden 
mutation may only need careful observation antepartum, the 
patient may have additional risk factors, such as a high body mass 
index (BMI), thus also putting them into a higher risk grade and 
need for antepartum prophylaxis.
The question arises whether patients should be tested for 
thrombophilia before pregnancy if there is a family history of 
VTE. A positive family history of VTE is a poor predictor of the 
presence of thrombophilia.[15] In any patient with a first-degree 
relative with VTE, whether a thrombophilic tendency has been 
proven or not, the VTE risk doubles, and in cases where the VTE 
event occurred in a family member ˂50 years of age, the risk rises 
up to 3-fold.[15] The RCOG guideline[9] therefore suggests testing 
the patient with a first-degree relative who had an unprovoked 
or oestrogen-related VTE before the age of 50 years. Patients may 
choose to undergo thrombophilia screening or specific testing for a 
thrombophilic abnormality that has been diagnosed in their family. 
Pretest counselling is necessary, because of the implications for the 
patient and her family. The RCOG guideline[9] suggests testing for 
antiphospholipid syndrome if an unprovoked VTE has occurred in 
a pregnant patient in the past (this may influence management of 
anticoagulation). 
Table 2. Risk factors to consider antepartum[12]
High risk Intermediate risk Low risk
• Previous unprovoked or pregnancy- or 
oestrogen-related VTE
• High-risk hereditary thrombophilia 
(compound heterozygous or homozygous 
for factor V Leiden or prothrombin 
gene mutation and some deficiencies 
of antithrombin) and a positive family 
history of VTE
• Antiphospholipid syndrome and previous 
VTE
• Single VTE related to a transient risk factor 
(not related to pregnancy or oestrogen use)
• Low- and intermediate-risk hereditary 
thrombophilia (some antithrombin 
deficiencies, protein S deficiency,  
protein C deficiency; heterozygous for  
factor V Leiden or prothrombin gene 
mutation) and a positive family history of VTE
• High-risk hereditary thrombophilia and no 
positive family history of VTE
• Antiphospholipid syndrome
• Non-obstetric surgery during pregnancy
• Medical comorbidities, e.g. cancer, heart 
failure, peripartum cardiomyopathy, 
active systemic lupus erythematosus, 
inflammatory polyarthropathy or 
inflammatory bowel disease; nephrotic 
syndrome; type 1 diabetes mellitus with 
nephropathy; sickle cell disease; current 
intravenous drug user
• Ovarian hyperstimulation syndrome  
(3 months after resolution)
• Age >35 years
• BMI ≥30 kg/m2
• Parity ≥3
• Smoker (at least 10 cigarettes per day)
• Family history of unprovoked or oestrogen-
related VTE in first-degree relative
• Low-risk thrombophilia
• Gross varicose veins
• Current systemic infection or perioperative 
infection
• Immobility, e.g. paraplegia, long-distance 
travel (>8 h), strict bedrest ≥7 d
• Pre-eclampsia with intrauterine growth 
restriction
• Multiple pregnancy
• In vitro fertilisation
• Dehydration/hyperemesis
• Antepartum
• Thromboprophylaxis indicated
• Clinical monitoring indicated • Early mobilisation and avoid dehydration
• Thromboprophylaxis if multiple (≥4) risk 
factors present
VTE = venous thromboembolism; BMI = body mass index.
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Various other risk factors (personal risks (e.g. BMI, smoking), pregnancy-
related risks (e.g. caesarean section) and medical comorbidities (e.g. 
autoimmune disorder)) are known to increase the risk of developing 
VTE, and thus the third question to ask the patient is the following:
Are there additional risk factors present?
The magnitude of this last group depends on the number of 
risk factors present, as well as the nature of the specific risk 
factors. Assigning weight to factors has been attempted, but not 
validated. It is also unclear whether risk factors have an additional 
or multiplicative role.[13] The 2018 American Society of Hematology 
(ASH) guideline[13] suggests considering (without previous VTE or 
thrombophilia) prophylaxis – only if more than one additional risk 
factor is present. The RCOG Green-top guideline[9] and the SASTH 
guideline[12] suggest considering thromboprophylaxis in intermediate 
risk factors (hospital admission, non-obstetric surgery during 
Ante- and postpartum 
prophylaxis
At least postpartum
Yes
Intermediate risk factors
Hospital admission
Non-obstetric surgery during pregnancy
Medical comorbidities
Ovarian hyperstimulation
Minor risk factors
Age >35 years
BMI ≥30 kg/m2
Parity ≥3
Smoker (>10 cigarettes per day)
Gross varicose veins
Current systemic infection or perioperative infection
Immobility, e.g. paraplegia, long-distance travel (>8 h), strict bedrest ≥7 d
Pre-eclampsia with intrauterine growth restriction
Multiple pregnancy
In vitro fertilisation
Dehydration/hyperemesis
ASH guideline: consider prophylaxis if >1 risk factor
RCOG and SASTH guidelines: consider ante- and postpartum prophylaxis if multiple 
minor risk factors (≥4), but mobilise and avoid dehydration 
Previous DVT?
Yes  No
>1 event
Unprovoked
Oestrogen/pregnancy 
related
Additional risk factors
Family history
Thrombophilia
Single episode
No known thrombophilia
Provoked event (major)
No additional risk factors
See Table 3
No
Yes
No
Pr
op
hy
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xi
s?
Fig. 1. Approach to initial assessment of venous thromboembolism risk in pregnancy. (DVT = deep-vein thrombosis; BMI = body mass index; 
ASH = American Society of Hematology; RCOG = Royal College of Obstetricians and Gynaecologists; SASTH = South African Society of Thrombosis and 
Haemostasis.)
Table 3. Thrombophilia in pregnancy
Type of thrombophilia Risk
Family history
(1st degree)
ASH, 2018[13]
Blood Reviews, 
2018[14]
AP PP AP PP
Factor V Leiden heterozygous Low risk Negative No* No* No No
Positive No* No* No Yes
Prothrombin mutation heterozygous Low risk Negative No* No* No No
Positive No* No* No Yes
Protein C  deficiency Intermediate risk Negative No* No* No No
Positive No* Yes* No Yes
Protein S deficiency Intermediate risk Negative No* No* No No
Positive No* Yes* No Yes
Antithrombin deficiency Intermediate risk Negative No* No* No No
Positive Yes* Yes* No Yes
Combined factor V Leiden and High risk Negative Yes* Yes* Yes Yes
prothrombin mutation Positive Yes* Yes* Yes Yes
Factor V Leiden homozygous High risk Negative Yes* Yes* No Yes
Positive Yes* Yes* Yes Yes
Prothrombin mutation homozygous High risk Negative No* Yes* No Yes
Positive Yes* Yes* Yes Yes
Antiphospholipid syndrome High risk Yes,
add aspirin
Yes,
add aspirin
Yes,
add aspirin
Yes, 
add aspirin
ASH = American Society of Hematology; AP = antepartum prophylaxis; PP = postpartum prophylaxis.
*Conditional recommendation, low evidence. 
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pregnancy, medical comorbidities and ovarian hyperstimulation 
syndrome (first-trimester-only prophylaxis)) and when multiple (≥4) 
minor risk factors (age >35 years, BMI ≥30 kg/m2, parity ≥3, smoker 
(at least 10 cigarettes per day), gross varicose veins, current systemic 
infection or perioperative infection, immobility, e.g. paraplegia, 
long-distance travel (>8 hours), strict bedrest ≥7 days, pre-eclampsia 
with intrauterine growth restriction, multiple pregnancy, in vitro 
fertilisation and dehydration/hyperemesis) are present. 
Evaluation of risk factors at the time of delivery/
postpartum
There are three groups of risk factors that should be considered at this 
time of pregnancy (Table 4 and Fig. 2). 
Which anticoagulant drugs are safe in 
pregnancy and during breastfeeding?[14]
Drugs that are safe during pregnancy and breastfeeding are listed 
in Table 5.
How are patients on anticoagulation 
managed if they are contemplating 
pregnancy?
When contemplating pregnancy, preconception counselling regarding 
risks for mother and baby is essential. The International Society on 
Thrombosis and Haemostasis (ISTH) specifically recommends that 
women of childbearing age be counselled regarding risk of novel 
oral anticoagulants (NOACs) (dabigatran, rivaroxaban, apixaban) 
in pregnancy owing to possible teratogenic effects.[16] The suggested 
Table 4. Risk factors to consider at time of delivery/postpartum[9]
High risk Intermediate risk Additional factors
• Anyone requiring antenatal prophylaxis
• Any previous VTE
• Caesarean section in labour
• Asymptomatic thrombophilia (inherited or 
acquired)
• BMI >40 kg/m2
• Prolonged hospital admission
• Medical comorbidities, e.g. heart or 
lung disease, SLE, cancer, inflammatory 
conditions, nephrotic syndrome, sickle cell 
disease, intravenous drug user
• Age >35 years
• Obesity (BMI >30 kg/m2)
• Parity ≥3
• Smoker
• Elective caesarean section
• Any surgical procedure in the puerperium
• Gross varicose veins
• Current systemic infection
• Immobility, e.g. paraplegia, symphysis pubis 
dysfunction, long-distance travel
• Pre-eclampsia
• Mid-cavity rotational operative delivery
• Prolonged labour (>24 h)
• PPH >1 L or blood transfusion
• At least 6 weeks’ postpartum prophylaxis • At least 7 days’ postpartum prophylaxis; 
if persisting or >3 risk factors, consider 
extending thromboprophylaxis 
• ≥2: at least 7 days’ postpartum prophylaxis, 
if persisting or >3 risk factors, consider 
extending thromboprophylaxis
• ˂2: early mobilisation and avoid dehydration
VTE = thromboembolism; BMI = body mass index; SLE = systemic lupus erythematosus; PPH = postpartum haemorrhage. 
At least 7 days' postpartum prophylactic LMWH, 
if persisting, or >3 risk factors, consider extending 
thromboprophylaxis
Caesarean section in labour
BMI >40 kg/m2
Prolonged hospital admission
Medical comorbidities, e.g. heart or 
lung disease, SLE, cancer, inammatory 
conditions, nephrotic syndrome, sickle 
cell disease, intravenous drug user
At least 7 days’ postpartum prophylaxis, 
if persisting or >3 risk factors, consider extending 
thromboprophylaxis
Age >35 years
Obesity (BMI >30 kg/m2)
Parity ≥3
Smoker
Elective caesarean section
Any surgical procedure in the puerperium
Gross varicose veins
Current systemic infection
Immobility, e.g. paraplegia, SPD, long-distance travel
Pre-eclampsia
Mid-cavity rotational operative delivery
Prolonged labour (>24 h)
PPH >1 L or blood transfusion
Antepartum prophylaxis
Yes No
Any previous VTE
Yes No
6 weeks' postpartum prophylaxis
See Table 3
Mobilisation,
avoid dehydration
Known thrombophilia
NoYes
NoYes
<2 risk factors
≥2 risk factors
Additional risk factors
Fig. 2. Approach to assessment of venous thromboembolism risk in pregnancy at delivery/postpartum.[9] (VTE = venous thromboembolism; 
LMWH = low-molecular-weight heparin; BMI = body mass index; SLE = systemic lupus erythematosus; SPD = symphysis pubis dysfunction; 
PPH = postpartum haemorrhage.) 
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management of a patient on anticoagulants contemplating pregnancy 
is shown in Table 6.[14]
Practical aspects of low-molecular-
weight heparin prophylaxis in 
pregnancy
Which patients should not receive low-molecular-
weight heparin as the drug of choice?
Unfractionated heparin (UFH) is indicated in patients with 
significant renal dysfunction and may be used if a shorter period 
of anticoagulation/urgent reversal is contemplated (peripartum). 
Fondaparinux (or danaparoid, which is currently not available South 
Africa (SA)) is the drug of choice in patients with heparin-induced 
thrombocytopenia (HIT) or a history of HIT. 
What dosage of low-molecular-weight heparin should 
patients receive for VTE prophylaxis? Should one 
measure effect?
Physiological changes (increased volume of distribution and renal 
clearance) during pregnancy alter the pharmacokinetics of drugs,[16] 
but until the study[17] evaluating required dosages for VTE prophylaxis 
in pregnancy is completed, the 2018 ASH guidelines suggest against 
the use of intermediate dosages in antepartum prophylaxis compared 
with standard dosages, and for the use of standard- or intermediate-
dose low-molecular-weight heparin (LMWH) for postpartum VTE 
prophylaxis.[13] The SASTH guideline[12] also suggests standard 
prophylactic dosages, but in view of the physiological changes in 
pregnancy, recommends that regular anti-factor X activity (FXa) 
measurement be done, especially in women at extremes of weight, 
with renal disease and severe pre-eclampsia. The RCOG guideline[9] 
suggests that routine monitoring of the platelet count not be done in 
pregnant patients, unless UFH is used. Both the SASTH guideline[12] 
and the Society of Obstetricians and Gynaecologists of Canada[18] 
suggest that baseline platelet count be done, followed a week later 
with screening for HIT. 
Standard dosages of LMWH are given in Table 7.
How long should VTE prophylaxis be continued?
Patients with a high VTE risk (such as those needing antepartum 
prophylaxis, previous VTE event, multiple risk factors) should 
continue with prophylaxis for 6 weeks postpartum, and at least 
for 10 days if at intermediate risk, with low-risk patients receiving 
thromboprophylaxis until discharged from hospital.[12] 
Which patients should receive thromboprophylaxis 
after caesarean delivery?
There is no clear consensus regarding which patients have a low 
enough risk not to receive thromboprophylaxis after elective 
caesarean delivery (CD). Emergency CD alone puts the patient in the 
intermediate-risk group of the RCOG[9] (with thromboprophylaxis 
indicated). This intermediate-risk group also includes patients 
with elective CD and an additional risk factor. Another guidance 
paper[1] suggests VTE prophylaxis if one of the following is present: 
prior VTE, antepartum immobilisation (strict bedrest >1 week), 
significant postpartum infection, postpartum haemorrhage (PPH) 
of at least 1 000 mL that requires reoperation, pre-eclampsia with 
growth restriction, significant medical comorbidities (systemic lupus 
erythematosus (SLE), heart disease, sickle cell disease) or known 
thrombophilia. Thromboprophylaxis is also indicated if ≥2 of the 
following are present (in emergency CD ≥1): PPH >1 000 mL without 
Table 5. Anticoagulants used in pregnancy
Drug
Drug passes the 
placenta
Drug safe/unsafe in 
pregnancy
Drug passes into 
breastmilk Drug safe/unsafe in breastfeeding
VKA Yes Unsafe Yes Safe
UFH No Safe Yes Safe
LMWH No Safe Yes Safe
Fondaparinux* Yes May be used* ? Safe
NOAC Yes Unsafe Yes Unsafe
Aspirin Yes Yes (up to 100 mg/d) Yes Yes (up to 100 mg/d)
VKA = vitamin K antagonist (warfarin); UFH = unfractionated heparin; LMWH = low-molecular-weight heparin; NOAC = novel oral anticoagulant.
*Fondaparinux should only be used if there are LMWH side-effects.
Table 6. Managing an anticoagulated patient who is planning a pregnancy
Drug Action Additional action
NOAC Switch to VKA or to LMWH before the pregnancy If switched to VKA, follow VKA path 
VKA (warfarin) Pregnancy test immediately after missed menstrual period
Reassess frequently 
If positive pregnancy test, switch to LMWH
Patient’s choice to switch early
Give oral vitamin K as soon as switched to 
LMWH
LMWH Continue with LMWH -
NOAC = novel oral anticoagulant; VKA = vitamin K antagonist (warfarin); LMWH = low-molecular-weight heparin. 
Table 7. Standard prophylactic dosages of LMWH[1] 
Drug Standard dose Intermediate dose*
Enoxaparin 40 mg daily 40 mg twice daily or 80 mg 
once daily
Nadroparin 2 850 U daily 3 800 U daily
Dalteparin 5 000 U daily 5 000 U twice daily or  
10 000 U once daily
Bemiparin 40 mg daily 60 mg once daily if <50 kg;  
90 mg once daily if >50 kg
LMWH = low-molecular-weight heparin. 
* LMWH adjusted to peak anti-factor Xa level (3 - 4 h after administration) to    
0.2 - 0.6 IU/mL.
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reoperation necessary, BMI >30 kg/m2, 
fetal growth restriction, pre-eclampsia, 
multi ple pregnancies and tobacco use during 
pregnancy (>10 cigarettes per day).
A practical approach is recommended by 
both SASTH[12] and the European Society 
of Anaesthesiology (ESA) VTE guideline 
task force:[19] all patients should receive 
thromboprophylaxis in hospital (ESA – 
except low-risk patients with elective CD), 
with the duration of thromboprophylaxis 
at least 6 weeks for high-risk patients and at 
least 7 days for low-risk patients. Mechanical 
prophylaxis after surgery and before starting 
LMWH should be left in place until the 
patient is mobilised and the LMWH effect is 
present.[20] Managing neuraxial blockade is 
discussed below.
What should be done if patients 
on low-molecular-weight heparin 
develop side-effects?
• Even though the risk of HIT in pregnancy 
is low with the use of LMWH (estimated 
at <0.1%),[21] if the diagnosis of HIT is 
considered (using the 4Ts score: tone 
of the uterus, trauma to the birth canal, 
tissue (retained placenta or abnormal 
placentation and thrombin)), the patient 
should be switched to a non-heparin 
anticoagulant (fondaparinux), and the 
appropriate testing done to confirm the 
diagnosis. If ruled out, the patient may 
continue receiving LMWH. 
• Heparin-induced skin reaction is often seen 
(1.8 - 42.0% of patients)[14] and switching to 
another LMWH often resolves the issue.
• Bleeding risk depends on the dosage of the 
anticoagulant and patient factors. Prior to 
prescribing thromboprophylaxis,[22] the 
patient’s bleeding history should always 
be evaluated. Risk of bleeding is highest 
at the time of delivery and options to 
reduce this risk are discussed below under 
management of labour.
• Osteoporosis risk is estimated to be low 
with prophylactic dosages of LMWH, but 
data are needed on therapeutic LMWH 
use in pregnancy. This risk is much higher 
with the use of UFH. Routine screening for 
osteoporosis in the pregnant patient is not 
mandatory.[14]
Specific hypercoagulable 
difficult situations
• Antithrombin (AT) deficiency. Heparin 
(especially UFH) acts as an anticoagulant 
via AT, and VTE despite adequate LMWH 
prophylaxis has been described.[23] 
Another problem is that some of the anti-
FXa laboratory methods add AT during 
testing; the laboratory value would then 
be unreliable in AT deficiency. These 
patients may need AT supplementation 
(not available in SA), and testing the 
effect of LMWH needs to be done with a 
method that does not add external AT in 
the laboratory.
• Antiphospholipid syndrome (APLS).[14] 
This acquired thrombophilia has a high 
risk of pregnancy complications. Patients 
with APLS (even without a previous histo-
ry of VTE and not on long-term prophy-
lactic anticoagulation before preg  nancy) 
should receive prophylactic LMWH ante-
partum and up to 6 weeks postpartum 
(there is an ongoing study to find the 
optimal dose).[24] Patients receiving thera-
peutic anticoagulation before pregnancy 
should continue with therapeutic LMWH 
antepartum, postpartum and during preg-
nancy. Additional aspirin (<100 mg daily) 
should also be given. Catastrophic APLS, 
although rare, seems to be triggered in preg-
nancy, and a specialist team should manage 
these patients. 
Diagnosis of VTE in 
pregnancy
A pregnant patient with signs or symp-
toms suggestive of DVT should be 
evaluated promptly and LMWH should be 
administered until the diagnosis has been 
excluded, unless there are contraindications 
to LMWH (15 - 24% of patients with DVT 
develop pulmonary embolism (PE), which 
is fatal in almost 15% of pregnant patients).[22] 
Until recently, pretest probability scoring 
systems (such as the modified Wells scoring 
system and the YEARS criteria, which 
include DVT present, haemoptysis and PE 
the most likely diagnosis) have not been used 
in the diagnosis of VTE during pregnancy. 
D-dimer testing has limited use to exclude 
VTE in pregnancy, as D-dimer values 
increase in pregnancy. Furthermore, the use 
of D-dimer testing in pregnancy remains 
controversial, as the RCOG guideline advises 
against such testing in this setting (a negative 
D-dimer is inadequate proof to exclude PE 
in pregnancy).[22] Fig. 3 shows the RCOG 
approach: if a DVT is clinically suspected, 
compression duplex ultrasonography should 
be undertaken. If this is negative, but there 
is a high level of suspicion, a repeat ultrasound 
examination should be done after 3 and 7 days.[22] 
If iliac vein thrombosis is suspected, magnetic 
resonance imaging (MRI) or a venogram may 
be done if ultrasonography is negative.
For the work-up of the pregnant woman 
presenting with a possible PE, the RCOG 
Green-top guideline[22] suggests the following 
(Fig. 4): Unless contraindicated, consider 
giving LMWH during work-up. The 
patient should have a chest radiograph and 
electrocardiogram (ECG) done urgently. If 
signs and symptoms of DVT are present, 
FBC, coagulation screen, urea and electrolytes, 
and liver function tests
Thrombophilia screen before therapy 
not recommended
MRI or venogram if 
symptoms suggestive 
of isolated iliac vein thrombosis
Clinical picture of venous thrombosis
Consider starting 
LMWH during work-up
Complete compression ultrasonography and iliac vein duplex ultrasonography
Positive Negative
Anticoagulant therapy Serial ultrasonography and 
clinical follow-up after 
3 and 7 days
Fig. 3. Suggested flow diagram for diagnosis of venous thrombosis (adapted from the Royal College 
of Obstetricians and Gynaecologists guideline[22]). (LMWH = low-molecular-weight heparin; 
FBC = full blood count; MRI = magnetic resonance imaging.)
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an ultrasound examination should be 
done, and if positive, no further testing is 
required (but the patient must be assessed 
for severity of the PE). If the ultrasound 
findings are negative, confirmation of the PE 
is either with a ventilation/perfusion (V/Q) 
scan or computed tomography pulmonary 
angiogram (CTPA). Radiation risk to the 
mother is the highest with CTPA, and 
radiation risk to the fetus is highest with a 
V/Q scan (radiation risk below the threshold 
for fetal teratogenicity, death or growth 
restriction, but a very small increased risk of 
childhood cancer development). Informed 
consent must be obtained from the mother 
before performing any of these tests. If the 
chest radiograph is abnormal, a CTPA is 
suggested rather than a V/Q (more specific 
for other pathological conditions). If the 
clinical suspicion is still high after the CTPA 
or V/Q test, alternative testing or repeat 
testing may be done, but anticoagulation 
must be continued until the diagnosis is 
definitely excluded. The ASH guideline[13] 
suggests a V/Q scan rather than CTPA for 
exclusion of PE. The European Society of 
Cardiology (ESC) 2019 acute pulmonary 
embolism management guideline,[25] however, 
suggests using the assessment of clinical 
probability, D-dimer measurement, com-
pression ultrasound examination, and CTPA 
to possibly safely exclude PE in pregnancy. 
With new CTPA techniques, radiation 
to the breasts of the mother is much less 
(such as reducing kilovoltage, reducing the 
anatomical coverage of the scan and reducing 
the contrast-monitoring component of the 
CTPA).[25] If a PE is diagnosed, its severity 
and the risk of early death should be assessed 
as soon as possible, and the patient referred 
to a multidisciplinary team with experience 
in the management of PE.
Treatment of VTE in 
pregnancy
All guidelines state that treatment of VTE 
in pregnancy should be with LMWH as 
the preferred drug.[13] UFH may be used 
in massive PE (cardiovascular collapse), 
or when VTE occurs at term.[3,22] Acute 
superficial vein thrombosis should also 
be treated with LMWH.[13] The dosage 
of LMWH needs to be therapeutic, and 
although traditionally given as a twice-daily 
dose, the ASH guideline[13] (low certainty) 
recommends that either once-daily or twice-
daily LMWH may be administered. Due to 
the half-life of LMWH, a twice-daily dosage 
is a more rational choice pharmacokineti-
cally.[3] Doses are titrated against the patient’s 
booking or early pregnancy weight. Routine 
anti-FXa measurement is not indicated 
(ASH guideline),[13] but regular anti-FXa 
measurement is suggested in the SASTH 
guideline[12] (for prophylaxis and therefore 
also for treatment). The RCOG Green-top 
guideline[22] suggests anti-FXa measure-
ment in cases of extremes of body weight 
(˂50 kg or >90 kg), and in the presence of 
complicating factors (e.g. renal dysfunction). 
Recommended baseline blood measurements 
are full blood count, coagulation screening, 
urea and electrolytes and liver function 
tests, but thrombophilia screening should 
not be done at the time of VTE.[22] Most 
patients with VTE need to be admitted to 
hospital. Treatment should be continued 
with therapeutic doses during the remainder 
of the pregnancy and at least for 6 weeks 
postpartum. If the patient has a high risk of 
osteoporosis, bleeding or an isolated distal 
DVT, 1 month of full-dose therapy decreased 
to 75% of the therapeutic dose may be 
considered.[1] If the VTE event occurred 
during the last trimester, at least 3 months of 
therapy should be given. With VTE at term, 
consideration should be given to UFH (much 
easier to use therapeutically).[22] Thrombolysis 
should only be considered in life-threatening 
VTE (massive PE, limb-threatening DVT), 
and must be managed by a team of 
experienced clinicians.[22] The 2018 ASH 
guideline[13] states that pregnant patients with 
acute PE and right ventricular dysfunction 
in the absence of haemodynamic instability 
should not receive thrombolysis (systemic 
thrombolytic therapy only in acute PE and 
life-threatening haemodynamic instability). 
Graduated elastic compression stockings to 
reduce oedema are suggested.[22] The only 
indication for the insertion of an inferior 
vena cava filter would be an acute VTE and 
if anticoagulation is contraindicated.[1]
Suggested dosages of LMWH and fonda-
parinux according to weight are described in 
Tables 8 and 9.
Managing labour 
in patients on 
anticoagulation
Anticoagulation at the time of labour poses 
a risk of bleeding, and all pregnant patients 
receiving antepartum thromboprophylaxis 
need a delivery plan.[12] This should be 
discussed early (~30 weeks’ gestation)[14] and 
includes mode of delivery, e.g. CD, induction 
of labour (scheduled delivery) or spontaneous 
labour and delivery. The decision should 
be based on obstetric indication,[12] but 
mostly depends on patient and physician 
preference. The ASH guideline[13] suggests 
scheduled delivery with prior discontin uation 
of anti coagulation in patients receiving 
therapeutic dosages of LMWH (24 hours 
before delivery). In patients receiving 
prophylactic dosages of LMWH, the ASH 
guideline suggests against scheduled 
delivery (conditional recommendation, with 
very little evidence), but LMWH should be 
discontinued 12 hours prior to delivery. If 
spontaneous labour occurs, the patient must 
be advised to discontinue LMWH at the 
first sign of labour (contraction, membrane 
High clinical suspicion: alternative method/repeat
Low clinical suspicion: discontinue LMWH, consider alternative diagnosis
Clinical picture of PE
Start LMWH, unless 
contraindicated
Urgent ECG and CXR
Signs and symptoms of DVT
Present
Compression duplex  ultrasonography
Positive
Anticoagulant therapy
Pretest probability scoring systems not reliable
FBC, coagulation screen, urea and electrolytes, and liver function tests
Thrombophilia screen before therapy not recommended
Absent CXR normal?
Negative
No
Yes
Perform CTPA
Perform V/Q scan
PE conrmed
PE not conrmed
Fig. 4. Suggested flow diagram for the diagnosis of pulmonary embolism (adapted from the Royal 
Collge of Obstetricians and Gynaecologists guideline[22]). (PE = pulmonary embolism; LMWH = 
low-molecular-weight heparin; FBC = full blood count; ECG = electrocardiogram; CXR = chest 
radiograph; DVT = deep-vein thrombosis; CTPA = computed tomography pulmonary angiogram; 
V/Q = ventilation/perfusion.) 
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rupture) or any vaginal bleeding. Switching from LMWH to UFH 
closer to delivery has been suggested in the very-high-risk patient 
to reduce the ‘time without anticoagulation period’, but this showed 
increased bleeding risk.[26] (UFH can be discontinued 4 - 6 hours 
before delivery.[27]) Attention should be paid to the mechanism of 
clotting (formation of thrombin), as well as to the other haemostatic 
factors (known as the 4 Ts).[3] The ESC guideline suggests active 
management of the third stage of labour with modified doses of 
oxytocin.[28] Wound drains (abdominal and rectus sheath) should 
be considered with CD and skin closure should be with interrupted 
sutures or staple clips.[9] Reintroduction of treatment should be started 
4 - 6 hours after vaginal delivery or 6 - 12 hours after CD (American 
College of Obstetricians and Gynecologists)[1] in the absence of 
postpartum haemorrhage and regional anaesthesia.[9] The Royal College 
of Obstetricians and Gynaecologists[9] guideline suggests avoiding 
the use of warfarin in the first 5 days after delivery, and for a longer 
period in the patient at risk of postpartum haemorrhage. Mechanical 
prophylactic measures should be left in situ until the patient is 
ambulatory and on anticoagulation again.
Managing neuraxial anaesthesia 
With CD, the risk for adverse intraoperative and postoperative events 
is lower with neuraxial anaesthesia than with general anaesthesia. 
It is also often the choice for anaesthesia during labour, because it 
contributes to minimising the urge to bear down before complete 
cervical dilation and decreases circulating catecholamines.[29] If the 
patient is on anticoagulation, it is crucial to evaluate the specific drug, 
dosage and time since administration before neuraxial anaesthesia. 
Knowledge of the patient’s platelet count and possible drugs that 
interfere with platelet function is necessary before administering 
neuraxial anaesthesia. Extreme caution is needed if any other 
drugs influencing coagulation are prescribed,[12] and concomitant 
antiplatelet therapy (aspirin/non-steroidal anti-inflammatory drugs 
(NSAIDs)) should not be administered with heparin if a neuraxial 
catheter is left in situ.[30] Aspirin should not be given for 5 - 7 days 
prior to neuraxial anaesthesia if the patient is receiving anticoagulant 
therapy. Women who have received neuraxial anaesthesia should 
Table 8. Initial therapeutic dosages of LMWH[22] 
Booking or early pregnancy 
weight, kg Enoxaparin dose, mg* Dalteparin dose, IU* Bemiparin dose, mg*
<50 40 bd or 60 once daily 5 000 bd or 10 000 once daily 60 once daily
50 - 69 60 bd or 90 once daily 6 000 bd or 12 000 once daily 90 once daily
70 - 89 80 bd or 120 once daily 8 000 bd or 16 000 once daily 120 once daily
90 - 109 100 bd or 150 once daily 10 000 bd or 20 000 once daily 90 - 100 kg: 120 once daily
110 - 125 120 bd or 180 once daily 12 000 bd or 24 000 once daily 100 - 125 kg: 180 once daily
>125 Discuss with haematologist Discuss with haematologist Discuss with haematologist
LMWH = low-molecular-weight heparin. 
*Anti-factor Xa testing required.
Table 9. Treatment dosages of fondaparinux*[23]
Booking or early pregnancy weight, kg Fondaparinux, mg
<50 2.5 once daily
51 - 75 5.0 once daily
76 - 100 7.5 daily
>100 10.0 daily
* Only to be used if there is a low-molecular-weight heparin side-effect, e.g. heparin-induced 
thrombocytopenia.
Table 10. Summary of most recent guidelines regarding neuraxial anaesthesia
Low-dose LMWH Higher-dose LMWH* Low-dose UFH†
Higher-dose 
UFH†
Fondaparinux
(prophylactic, 2.5 mg)‡
Period after last dose given Wait for ≥12 h Wait ≥24 h Wait ≥4 - 6 h Wait ≥24 h 
(intermediate 
dose ≥12 h)
Wait 36 - 42 h
Restarting anticoagulation after 
neuraxial block§
Wait ≥12 h Wait ≥24 h[29] Wait ≥1 h Wait ≥1 h Wait 12 h
Restarting anticoagulation after
insertion of indwelling catheter§
Wait ≥4 h Maintain anti-
coagulation with 
low-dose LMWH; 
therefore, wait ≥4 h, 
no NSAIDs
Wait ≥1 h Maintain with 
low-dose UFH; 
therefore,
wait ≥1 h
-
Removal of catheter after last 
anticoagulant
Wait ≥12 h Low-dose LMWH 
maintenance;  
therefore, wait ≥12 h
Wait ≥4 - 6 h Low-dose UFH; 
therefore, wait  
≥4 - 6 h
-
Restarting anticoagulant after 
removal of catheter 
Wait ≥4 h Wait ≥4 h Wait ≥1 h Wait ≥1 h Wait 6 - 12 h
LMWH = low-molecular-weight heparin; UFH = unfractionated heparin; NSAIDs = non-steroidal anti-inflammatory drugs.
*Anti-factor Xa assay may be done. 
†Activated partial thromboplastin time to be determined. 
‡Neuraxial anaesthesia impractical with fondaparinux.
§If blood is noted in the needle or neuraxial catheter, LMWH should be delayed for at least 24 h.
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be monitored closely for the development of spinal haematoma 
(mandatory for a minimum of 12 hours; ideally for 72 hours).[12] 
Table 10 shows some of the suggested guidelines that have been 
published in the past year, but the SOAP guideline states clearly 
that it ‘is not intended to set out a legal standard of care and does 
not replace medical care or the judgment of the responsible medical 
professional considering all the circumstances presented by an individual 
patient’.[30] It is also applicable to the patient with normal renal 
function in the context of pregnancy and body weight >40 kg, with no 
other known contraindications to neuraxial anaesthesia.[30] The ASRA 
guideline[28] is also incorporated in Table 10. It is important that each 
unit has an easily accessible protocol for managing these patients. If 
spontaneous labour occurs while the patient is on anticoagulation, 
neuraxial anaesthesia should not be administered if labour is within 
the contraindicated timeframe.
Summary
Managing VTE in the pregnant patient is complex, and although 
guidelines have been discussed in this article, a team approach, taking 
all factors in the individual patient into consideration, is essential. 
It is impossible to discuss all the permutations of thrombotic and 
bleeding risk factors in every patient. The reader is advised to read 
the excellent recent reviews, including the first statement by SOAP 
regarding anaesthetic management in pregnant patients receiving 
thromboprophylaxis.[30]
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